{
    "ticker": "RITR",
    "name": "Ritter Pharmaceuticals, Inc.",
    "description": "Ritter Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative therapies for gastrointestinal diseases. Founded in 2007 and based in Los Angeles, California, Ritter is dedicated to addressing unmet medical needs through its proprietary therapeutic candidates. The company primarily concentrates on developing treatments for patients suffering from lactose intolerance, a condition that affects millions worldwide. Ritter's lead product candidate, RP-G28, is a novel therapy designed to improve the digestion of lactose in individuals with lactose intolerance. By combining a unique formulation with a thorough understanding of gastrointestinal biology, Ritter aims to enhance the quality of life for patients who avoid dairy products due to discomfort. The company is committed to advancing its clinical programs and has made significant progress in clinical trials, showcasing the potential effectiveness and safety of its therapies. Ritter is also exploring additional indications within the gastrointestinal space, positioning itself as a leader in gut health solutions. The company\u2019s mission is rooted in scientific innovation and patient-centric approaches, striving to bring new hope to those affected by digestive disorders. With a dedicated team of professionals and a strong pipeline of products, Ritter Pharmaceuticals is poised to make substantial contributions to the biopharmaceutical industry.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2007",
    "website": "https://www.ritterpharmaceuticals.com",
    "ceo": "Dr. Andrew Ritter",
    "social_media": {
        "twitter": "https://twitter.com/RitterPharma",
        "linkedin": "https://www.linkedin.com/company/ritter-pharmaceuticals"
    },
    "investor_relations": "https://ir.ritterpharmaceuticals.com",
    "key_executives": [
        {
            "name": "Dr. Andrew Ritter",
            "position": "CEO"
        },
        {
            "name": "Robert D. Sweeney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RP-G28"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ritter Pharmaceuticals, Inc. | Innovative Therapies for Gastrointestinal Diseases",
        "meta_description": "Learn about Ritter Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for gastrointestinal diseases, including lactose intolerance.",
        "keywords": [
            "Ritter Pharmaceuticals",
            "Gastrointestinal diseases",
            "Lactose intolerance",
            "RP-G28",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Ritter Pharmaceuticals known for?",
            "answer": "Ritter Pharmaceuticals is known for developing innovative therapies for gastrointestinal diseases, particularly lactose intolerance."
        },
        {
            "question": "Who is the CEO of Ritter Pharmaceuticals?",
            "answer": "Dr. Andrew Ritter is the CEO of Ritter Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Ritter Pharmaceuticals headquartered?",
            "answer": "Ritter Pharmaceuticals is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What is the main product of Ritter Pharmaceuticals?",
            "answer": "The main product of Ritter Pharmaceuticals is RP-G28, a therapy for lactose intolerance."
        },
        {
            "question": "When was Ritter Pharmaceuticals founded?",
            "answer": "Ritter Pharmaceuticals was founded in 2007."
        }
    ],
    "competitors": [
        "AMRN",
        "VTL",
        "PTGX"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "MSFT",
        "NFLX"
    ]
}